Search Results

Twelve-Month MIMICS-2 Data Presented for Veryan Medical's BioMimics 3D Stent

January 30, 2018—Veryan Medical Ltd. announced that Professor Thomas Zeller, MD, presented the 12-month safety and efficacy data from the MIMICS-2 study at LINC 2018: the Leipzig Interventional Course held January 30 to February 2 in Leipzig, Germany.

DEFINITIVE AR 30-Day Results Presented on Directional Atherectomy Plus DCB

October 10, 2013—The DEFINITIVE AR study's 30-day results were presented by Professor Thomas Zeller, MD, at a late-breaking trial session during the VIVA 2013: Vascular Interventional Advances conference, being held October 8–11 in Las Vegas, Nevada.

Update Presented on Trial of Reflow's Temporary Spur Stent System for BTK Treatment

November 5, 2019—VIVA Physicians announced that Professor Thomas Zeller, MD, provided an update on the DEEPER OUS study in a late-breaking clinical trial session at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.

Med Alliance's SELUTION FIM Study Achieves Primary Endpoint

January 31, 2018—Med Alliance announced that primary endpoint data from the first-in-man (FIM) study of the company's Selution sirolimus-coated balloon were presented by Principal Investigator Professor Thomas Zeller, MD, at LINC 2018, the Leipzig Interventional Course held January 30 to February 2 in Leipzig, Germany.

ILLUMENATE Global 12-Month Data Presented for Spectranetics' Stellarex DCB

January 24, 2017—The Spectranetics Corporation announced that the final 12-month results from the ILLUMENATE Global Study of the Stellarex drug-coated balloon (DCB) were presented by Professor Thomas Zeller, MD, at LINC 2017, the Leipzig Interventional Course in Leipzig, Germany.

Veryan Medical's MIMICS-2 36-Month Data Presented at CX 2020

June 9, 2020—Veryan Medical Ltd., an Otsuka Medical Devices company, announced that the 36-month results from the company's MIMICS-2 study were presented by Professor Thomas Zeller, MD, at CX 2020 Live, the virtual Charing Cross Symposium, which takes place online with programs every Tuesday and Thursday from May 26 to June 25.

NovoStent's Samba Results Presented at PCR

May 25, 2010—NovoStent Corporation (Mountain View, CA) announced the 6-month results of a European clinical trial evaluating the use of its Samba stent and delivery system to treat superficial femoral artery and popliteal artery disease.

Med Alliance's Selution DCB Demonstrates Safety and Efficacy in Long Lesions

March 6, 2018—Med Alliance announced that findings from the first-in-man (FIM) study of the company's Selution sirolimus-coated balloon were presented by Principal Investigator Professor Thomas Zeller, MD, at CRT 2018, the Cardiovascular Research Technologies conference held March 3–6 in Washington, DC.

Interim Data From the MIMICS-3D Registry Presented for Veryan's BioMimics 3D Stent

November 6, 2018—Veryan Medical Ltd. announced interim data from the MIMICS-3D registry of the company’s BioMimics three-dimensional (3D) helical stent that were presented by Professor Thomas Zeller, MD, at the VIVA 18, Vascular Interventional Advances, conference held November 5–8 in Las Vegas, Nevada.

NovoStent's 6-Month Femoropopliteal Trial Results Presented for Samba Stent

May 25, 2010—NovoStent Corporation (Mountain View, CA) announced the 6-month results of a European clinical trial evaluating the use of its Samba stent and delivery system to treat superficial femoral artery (SFA) and popliteal artery disease. Professor Thomas Zeller, MD, presented the 6-month follow-up data at the EuroPCR 2010 conference in Paris.

Two-Year Data Presented for Veryan's BioMimics 3D Nitinol Stent

November 4, 2014—Veryan Medical Ltd announced that 2-year data from the MIMICS study were presented during the late-breaking clinical trials session at the VIVA 2014: Vascular InterVentional Advances meeting in Las Vegas, Nevada.

Performance of Veryan Medical's BioMimics 3D Helical Stent Assessed in Post Hoc Analysis of MIMICS Study

September 12, 2017—Veryan Medical Ltd. announced new data from the MIMICS study of the company’s BioMimics three-dimensional (3D) helical stent that were presented by Professor Thomas Zeller, MD, at the VIVA 17, Vascular Interventional Advances, conference held September 11–14 in Las Vegas, Nevada.

Twelve-Month ILLUMENATE Global Study Results Published for the Stellarex DCB

December 11, 2017—The final 12-month results from the ILLUMENATE Global study were published by Herman Schroë, MD, et al online ahead of print in Catheterization and Cardiovascular Interventions (CCI).

Four-Year Data Presented From Medtronic's IN.PACT Global Study

November 5, 2019—Medtronic announced that data from the IN.PACT Global Study reinforce the long-term durability and safety of the In.Pact Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

MedAlliance's Selution SLR Sustains Safety and Efficacy at 2 Years in First-in-Human Trial

November 5, 2019—MedAlliance SA, a Switzerland-based medical technology company, announced that 2-year data from the first-in-human study of the company’s Selution SLR sirolimus-eluting balloon were presented by Professor Thomas Zeller, MD, the study’s Principal Investigator, at VIVA 2019, the Vascular InterVentional Advances meeting held November 4–7 in Las Vegas, Nevada.

Covidien Presents 12-Month DEFINITIVE AR Results

November 4, 2014—Covidien plc announced 12-month results of the DEFINITIVE AR study, which is designed to identify the clinical benefits of plaque removal using directional atherectomy followed by treatment with a drug-coated balloon (DCB).

Enrollment Begins in Covidien's DEFINITIVE AR Study

August 3, 2011—Covidien (Mansfield, MA) announced the start of patient enrollment in the DEFINITIVE AR antirestenosis study.

5-Year Data From IN.PACT Global Study Show Sustained Safety and Efficacy for Medtronic’s In.Pact Admiral DCB

November 6, 2020—Five-year data from the IN.PACT Global study evaluated the real-world performance of the In.Pact Admiral drug-coated balloon (DCB) in patients with peripheral artery disease in the superficial femoral and popliteal arteries.